Should we continue to use the term non-small-cell lung cancer?

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Gazdar, A F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR;

ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INVASION; CANCER SURVIVAL; CONFERENCE PAPER; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NOMENCLATURE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; TERMINOLOGY AS TOPIC;

EID: 78649368854     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq372     Document Type: Conference Paper

References (27)

1. MedicineNet.com. Lung cancer glossary of terms. http://www.medicinenet.com/lung_cancer/glossary.htm (27 July 2010, date last accessed).
2. DeVita VT Jr, Lawrence TS, Rosenberg SA et al. (eds). Cancer Principles and Practice of Oncology, 8th edn. Philadelphia: Lippincott, Williams and Wilkins; 2008.
3. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nature reviews 2007; 7: 778-790.
4. Brambilla E, Travis WD, Colby TV et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001; 18: 1059-1068.
5. Travis W. IASLC/ATS/ERS International multidisciplinary classification of lung adenocarcinoma. J Thoracic Oncol. 2010; In Press.
6. Liebow AA. Bronchiolo-alveolar carcinoma. Adv Intern Med 1960; 10: 329-358.
7. Hajdu SI. The story of bronchioloalveolar carcinoma. Ann Clin Lab Sci 2005; 35: 336-338.
8. Noguchi M. Stepwise progression of pulmonary adenocarcinoma-clinical and molecular implications. Cancer Metastasis Rev 2010; 29: 15-21.
9. Noguchi M, Morikawa A, Kawasaki M et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 1995; 75: 2844-2852.
10. Miller VA, Kris MG, Shah N et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103-1109.
11. Weir BA, Woo MS, Getz G et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450: 893-898.
12. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010; 29: 23-36.
13. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer 2006; 6: 735-741.
14. Motoi N, Szoke J, Riely GJ et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008; 32: 810-827.
15. Kaira K, Horie Y, Ayabe E et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol 2010; 5: 460-465.
16. Finberg KE, Sequist LV, Joshi VA et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 2007; 9: 320-326.
17. Wong DW, Leung EL, So KK et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115: 1723-1733.
18. Scagliotti GV, De Marinis F, Rinaldi M et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol 2009; 4: 1568-1571.
19. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
20. Azzoli CG, Baker S, Jr, Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
21. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28 (Suppl 1): S24-S31.
22. Shigematsu S, Lin L, Takahashi T et al. Clinical and biological features associated with Epidermal Growth Factor Receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-346.
23. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
24. Gandhi J, Zhang J, Xie Y et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009; 4: e4576.
25. Jorda M, Gomez-Fernandez C, Garcia M et al. P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Cancer Cytopathol 2009; 117: 46-50.
26. Loo PS, Thomas SC, Nicolson MC et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010; 5: 442-447.
27. Landi MT, Zhao Y, Rotunno M et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010; 16: 430-441.